A shingles vaccine may have had an unexpected effect: fewer people in one study were diagnosed with dementia after they became eligible to receive it. The finding comes from a large study of health records in Wales, where a rule based on date of birth created a natural comparison between people who could receive the vaccine and people just outside the eligibility group.
The result is striking, but it is not a recommendation to get vaccinated to prevent dementia. The study examined an older vaccine, and its design cannot settle every question about cause and effect. It does, however, add an important piece of evidence to a growing research question: could preventing some infections also influence brain health later in life?
A birthday created a research opportunity
In 2013, Wales introduced a shingles vaccination program for older adults. Eligibility was tied to a birth-date cutoff. Researchers used that rule to compare people born just on either side of the cutoff—groups likely to be similar in age and many other respects, but with different eligibility for vaccination.
This approach is called a natural experiment. Rather than randomly assigning people to get a vaccine, researchers study a real-world rule that separates groups in a way that can approximate an experiment. In this case, the key question was whether dementia diagnoses later differed between those eligible for vaccination and those who were not.
The study, published in Nature, reported about a 20% relative reduction in new dementia diagnoses among people who became eligible over the follow-up period. That is a relative comparison, not a claim that vaccination prevented dementia in one in five people. Nor does it mean every person who received the vaccine benefited. The researchers assessed diagnoses recorded in health data; the result describes a difference between groups, not a direct measure of changes in every person’s underlying brain health.
What the result can—and cannot—show
The cutoff strengthens the study because people born close to it are less likely to differ sharply in age or life history than groups chosen in a less precise way. But eligibility is not the same as vaccination: not everyone offered a vaccine gets one. The analysis therefore helps estimate the effect of being eligible for the program, rather than providing a simple, definitive measure of what the injection did to every recipient.
It also remains an observational study, not a randomized trial designed to test dementia prevention. Health records can miss or delay diagnoses, and a diagnosis is not the same thing as the onset of disease. The findings are an association shaped by a useful natural experiment—not proof that the vaccine prevents dementia, or that the result will apply to everyone.
There is a plausible reason researchers are interested. The shingles vaccine prevents many cases of shingles, which occurs when the virus that causes chickenpox reactivates in the body. Scientists have proposed that infections, immune responses or inflammation could affect the brain. But this study did not establish a mechanism. It cannot tell us whether any difference in dementia diagnoses arose from preventing shingles, from another biological effect, or from factors the analysis could not fully account for.
The vaccine matters
The Welsh program used Zostavax, a live-attenuated shingles vaccine. That detail matters when interpreting the result today. The U.S. Centers for Disease Control and Prevention recommends Shingrix, a different, non-live vaccine, to prevent shingles and its complications in adults aged 50 and older, and in certain immunocompromised adults aged 19 and older. The Welsh finding does not demonstrate that Shingrix prevents dementia.
It would be a mistake to treat “shingles vaccine” as one interchangeable product or to turn an intriguing result into a new dementia-prevention promise. The study offers a reason to investigate further, not a reason to change vaccination decisions on its own. People should follow current vaccine guidance and discuss individual questions with a health professional.
A clue worth testing
Dementia is an umbrella term for conditions that impair memory, thinking or daily functioning; it is not a single disease with one cause. Researchers are studying many possible influences on brain health, including cardiovascular health, infections and immune function. A population-level result like this one can help identify a question that deserves more testing—but it cannot answer that question by itself.
The next steps include checking whether similar patterns appear in other populations and with other vaccines, and determining whether any effect is specific to the older live vaccine. Researchers will also need to distinguish a true change in dementia risk from a change in who is diagnosed, when they are diagnosed, or how their health-care use differs.
For now, the most defensible takeaway is modest but meaningful: a vaccine program designed to prevent shingles was associated with fewer new dementia diagnoses in a carefully studied group of older adults. That unexpected link gives scientists a promising lead. It does not yet make a shingles vaccine a proven tool for preventing dementia.
